olmesartan has been researched along with Dyslipidemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DiNicolantonio, JJ; Elisaf, MS; Liberopoulos, EN; Rizos, CV; Tellis, K; Tselepis, AD | 1 |
| Kawamori, R; Miyazaki, S; Okuda, Y; Sato, Y; Shirayama, M; Teramoto, T; Teramukai, S | 1 |
| Barkas, F; Elisaf, MS; Liamis, G; Liberopoulos, EN; Moutzouri, E; Rizos, CV | 1 |
| Arao, T; Mori, H; Nishida, K; Okada, Y; Tanaka, Y | 1 |
3 trial(s) available for olmesartan and Dyslipidemia
| Article | Year |
|---|---|
Combining rosuvastatin with angiotensin-receptor blockers of different PPARĪ³-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Angiotensin II Type 1 Receptor Blockers; Aryldialkylphosphatase; Benzimidazoles; Benzoates; Biomarkers; Biphenyl Compounds; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Irbesartan; Lipoproteins, HDL; Male; Middle Aged; PPAR gamma; Prediabetic State; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Telmisartan; Tetrazoles; Treatment Outcome | 2015 |
Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.
Topics: Aged; Blood Glucose; Dihydropyridines; Drug Therapy, Combination; Dyslipidemias; Endpoint Determination; Fasting; Female; Fluorobenzenes; Humans; Hypertension; Imidazoles; Insulin Resistance; Male; Middle Aged; Nitrobenzenes; Piperazines; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Tetrazoles; Treatment Outcome | 2013 |
Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Resistance; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Middle Aged; Telmisartan; Tetrazoles | 2013 |
1 other study(ies) available for olmesartan and Dyslipidemia
| Article | Year |
|---|---|
Lipid and blood pressure control for the prevention of cardiovascular disease in hypertensive patients: a subanalysis of the OMEGA study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Case-Control Studies; Dyslipidemias; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Lipids; Male; Middle Aged; Prognosis; Prospective Studies; Tetrazoles | 2015 |